LUNG · XBRL financial data

Pulmonx financial statements, every fiscal year

The same tables from 8 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (LUNG's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	32,733	48,416	53,662	68,675	83,789	90,497
Cost of goods and services sold	11,531	12,786	13,797	17,923	21,788	23,358
Gross profit	21,202	35,630	39,865	50,752	62,001	67,139
Research and development	7,460	13,063	15,397	18,080	17,570	19,491
Selling, general and administrative	46,074	69,871	83,105	94,607	102,135	101,311
Total operating expenses	53,534	82,934	98,502	112,687	119,705	120,802
Operating income (loss)	(32,332)	(47,304)	(58,637)	(61,935)	(57,704)	(53,663)
Interest income	213	400	1,529	5,568	5,061	2,651
Interest expense	3,181	829	1,066	3,232	3,507	3,155
Other income (expense)	3,282	(585)	(396)	(673)	256	790
Income tax expense (benefit)	213	343	353	571	500	626
Net income (loss)	(32,231)	(48,661)	(58,923)	(60,843)	(56,394)	(54,003)
Earnings per share, basic USD per share	(3.16)	(1.35)	(1.59)	(1.60)	(1.44)	(1.33)
Earnings per share, diluted USD per share	(3.16)	(1.35)	(1.59)	(1.60)	(1.44)	(1.33)
Weighted average shares, basic thousands of shares	10,185	36,129	37,097	37,975	39,111	40,686
Weighted average shares, diluted thousands of shares	10,185	36,129	37,097	37,975	39,111	40,686

Fiscal years (LUNG's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	231,561	148,480	101,736	83,547	70,905	69,751
Marketable securities	0	31,561	39,402	—	—	—
Marketable securities, non-current	0	10,941	5,924	—	—	—
Accounts receivable	4,228	6,562	8,677	12,105	13,120	12,072
Inventory	10,741	16,285	14,564	16,743	16,915	15,845
Prepaid and other current assets	3,228	4,883	4,343	4,235	4,474	3,758
Total current assets	249,989	208,002	168,953	150,422	136,248	101,684
Property and equipment, net	1,474	4,814	4,694	4,028	2,907	2,220
Right-of-use asset	8,976	8,075	5,806	3,406	18,545	18,028
Goodwill	2,333	2,333	2,333	2,333	2,333	2,333
Total assets	263,708	235,173	193,676	177,781	162,850	129,291
Accounts payable	1,472	1,582	1,758	1,497	3,827	3,905
Accrued liabilities	8,651	13,366	13,276	16,234	16,472	14,556
Current portion of long-term debt	0	—	—	—	—	—
Total current liabilities	12,526	17,550	18,492	23,157	24,437	20,058
Long-term debt	—	17,324	17,234	35,089	34,002	36,989
Lease liability, non-current	7,618	6,844	3,849	1,106	18,515	18,059
Total liabilities	37,574	41,934	39,669	59,466	77,041	75,175
Accumulated deficit	(242,734)	(291,395)	(350,318)	(411,161)	(467,555)	(521,558)
Total stockholders' equity	226,134	193,239	154,007	118,315	85,809	54,116
Total liabilities and equity	263,708	235,173	193,676	177,781	162,850	129,291
Common shares outstanding (cover page) thousands of shares	35,690	37,019	37,648	38,537	39,796	42,237

Fiscal years (LUNG's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(32,231)	(48,661)	(58,923)	(60,843)	(56,394)	(54,003)
Stock-based compensation	3,197	10,530	16,445	22,101	22,955	21,233
Net cash from operating activities	(30,633)	(41,388)	(45,083)	(37,610)	(31,537)	(32,376)
Purchases of property and equipment	911	3,671	1,318	807	1,447	452
Net cash from investing activities	12,694	(46,255)	(4,225)	(2,007)	17,476	30,482
Share repurchases	21	26	27	0	—	—
Proceeds from long-term debt	—	—	0	20,000	0	—
Net cash from financing activities	234,831	4,456	2,419	21,400	1,363	833
Net change in cash	217,025	(83,081)	(46,744)	(18,183)	(12,622)	(1,153)

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Pulmonx	52,690	22,835	(3,183)*	43.6M	8.5 quarters	Q3 FY26 10-QSep 30, 2026
Microbot Medical	3,152	241	(4,989)*	67.2M	13.5 quarters	Q2 FY26 10-QJun 30, 2026
TriSalus Life Sciences	46,288	11,407	(10,129)*	61.6M	4.6 quarters	Q2 FY26 10-QJun 30, 2026
Fonar	53,650	26,472	1,580*	not reported	—	Q3 FY26 10-QMar 31, 2026
CVRx	64,586	15,705	(8,826)*	26.6M	7.3 quarters	Q2 FY26 10-QJun 30, 2026
LENSAR	13,565	16,495	(127)*	12.3M	106.8 quarters	Q2 FY26 10-QJun 30, 2026
Accuray	40,623	100,919*	2,427*	119.4M	—	Q4 FY26 10-KJun 30, 2026
KORU Medical Systems	8,288	12,045	216*	46.2M	—	Q2 FY26 10-QJun 30, 2026
Carlsmed	46,244	not reported	(7,358)*	27.3M	9.5 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.